vs
Side-by-side financial comparison of Broadway Financial Corp (BYFC) and Taysha Gene Therapies, Inc. (TSHA). Click either name above to swap in a different company.
Broadway Financial Corp is the larger business by last-quarter revenue ($9.4M vs $5.5M, roughly 1.7× Taysha Gene Therapies, Inc.). Broadway Financial Corp runs the higher net margin — 1934.0% vs -507.8%, a 2441.7% gap on every dollar of revenue. On growth, Taysha Gene Therapies, Inc. posted the faster year-over-year revenue change (171.3% vs 10.1%). Over the past eight quarters, Taysha Gene Therapies, Inc.'s revenue compounded faster (26.8% CAGR vs 9.7%).
Virtu Financial, Inc. is an American high-frequency trading company. The company went public on the Nasdaq in 2015.
Taysha Gene Therapies, Inc. is a clinical-stage biotechnology company specializing in developing adeno-associated virus (AAV)-based gene therapies for rare monogenic central nervous system disorders with high unmet medical needs. Its core pipeline targets serious life-threatening neurological conditions, with primary operations and market focus across North America and European regions.
BYFC vs TSHA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $9.4M | $5.5M |
| Net Profit | $1.0M | $-27.9M |
| Gross Margin | — | — |
| Operating Margin | — | -516.0% |
| Net Margin | 1934.0% | -507.8% |
| Revenue YoY | 10.1% | 171.3% |
| Net Profit YoY | -21.8% | -48.3% |
| EPS (diluted) | $0.02 | $-0.08 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $9.4M | $5.5M | ||
| Q3 25 | $9.0M | $0 | ||
| Q2 25 | $8.1M | $2.0M | ||
| Q1 25 | $8.3M | $2.3M | ||
| Q4 24 | $8.6M | $2.0M | ||
| Q3 24 | $8.7M | $1.8M | ||
| Q2 24 | $8.2M | $1.1M | ||
| Q1 24 | $7.8M | $3.4M |
| Q4 25 | $1.0M | $-27.9M | ||
| Q3 25 | $-23.9M | $-32.7M | ||
| Q2 25 | $752.0K | $-26.9M | ||
| Q1 25 | $-2.7M | $-21.5M | ||
| Q4 24 | $1.3M | $-18.8M | ||
| Q3 24 | $516.0K | $-25.5M | ||
| Q2 24 | $256.0K | $-20.9M | ||
| Q1 24 | $-154.0K | $-24.1M |
| Q4 25 | — | -516.0% | ||
| Q3 25 | -256.2% | — | ||
| Q2 25 | 12.8% | -1347.1% | ||
| Q1 25 | -45.3% | -930.5% | ||
| Q4 24 | 21.7% | -985.8% | ||
| Q3 24 | 8.5% | -1448.4% | ||
| Q2 24 | 4.8% | -1915.4% | ||
| Q1 24 | -2.9% | -713.3% |
| Q4 25 | 1934.0% | -507.8% | ||
| Q3 25 | -264.2% | — | ||
| Q2 25 | 9.3% | -1353.6% | ||
| Q1 25 | -32.3% | -935.2% | ||
| Q4 24 | 15.3% | -929.0% | ||
| Q3 24 | 5.9% | -1427.5% | ||
| Q2 24 | 3.1% | -1882.0% | ||
| Q1 24 | -2.0% | -705.4% |
| Q4 25 | $0.02 | $-0.08 | ||
| Q3 25 | $-2.86 | $-0.09 | ||
| Q2 25 | $0.00 | $-0.09 | ||
| Q1 25 | $-0.39 | $-0.08 | ||
| Q4 24 | $0.07 | $-0.07 | ||
| Q3 24 | $-0.03 | $-0.10 | ||
| Q2 24 | $0.02 | $-0.09 | ||
| Q1 24 | $-0.02 | $-0.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $10.5M | $319.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $262.8M | $246.9M |
| Total Assets | $1.3B | $343.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $10.5M | $319.8M | ||
| Q3 25 | $19.7M | $297.3M | ||
| Q2 25 | $29.5M | $312.8M | ||
| Q1 25 | $15.8M | $116.6M | ||
| Q4 24 | $61.4M | $139.0M | ||
| Q3 24 | $97.1M | $157.7M | ||
| Q2 24 | $89.8M | $172.7M | ||
| Q1 24 | $67.1M | $124.0M |
| Q4 25 | $262.8M | $246.9M | ||
| Q3 25 | $261.7M | $219.0M | ||
| Q2 25 | $284.7M | $248.7M | ||
| Q1 25 | $283.6M | $55.1M | ||
| Q4 24 | $285.0M | $71.5M | ||
| Q3 24 | $286.2M | $88.8M | ||
| Q2 24 | $282.1M | $108.9M | ||
| Q1 24 | $281.1M | $53.8M |
| Q4 25 | $1.3B | $343.3M | ||
| Q3 25 | $1.3B | $316.6M | ||
| Q2 25 | $1.2B | $333.3M | ||
| Q1 25 | $1.3B | $138.4M | ||
| Q4 24 | $1.3B | $160.4M | ||
| Q3 24 | $1.4B | $180.2M | ||
| Q2 24 | $1.4B | $200.4M | ||
| Q1 24 | $1.4B | $153.0M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $230.0K | $-26.7M |
| Free Cash FlowOCF − Capex | $-13.0K | — |
| FCF MarginFCF / Revenue | -0.1% | — |
| Capex IntensityCapex / Revenue | 2.6% | — |
| Cash ConversionOCF / Net Profit | 0.22× | — |
| TTM Free Cash FlowTrailing 4 quarters | $2.3M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $230.0K | $-26.7M | ||
| Q3 25 | $3.8M | $-24.2M | ||
| Q2 25 | $3.0M | $-20.2M | ||
| Q1 25 | $-4.3M | $-22.0M | ||
| Q4 24 | $1.4M | $-18.3M | ||
| Q3 24 | $6.1M | $-21.6M | ||
| Q2 24 | $9.8M | $-21.5M | ||
| Q1 24 | $-11.7M | $-19.8M |
| Q4 25 | $-13.0K | — | ||
| Q3 25 | $3.7M | $-24.3M | ||
| Q2 25 | $3.0M | — | ||
| Q1 25 | $-4.4M | — | ||
| Q4 24 | $1.3M | $-18.3M | ||
| Q3 24 | $6.1M | $-21.6M | ||
| Q2 24 | $9.7M | $-21.7M | ||
| Q1 24 | $-11.7M | $-19.9M |
| Q4 25 | -0.1% | — | ||
| Q3 25 | 41.1% | — | ||
| Q2 25 | 37.0% | — | ||
| Q1 25 | -52.4% | — | ||
| Q4 24 | 14.7% | -905.5% | ||
| Q3 24 | 69.6% | -1210.9% | ||
| Q2 24 | 118.9% | -1951.9% | ||
| Q1 24 | -149.7% | -584.5% |
| Q4 25 | 2.6% | — | ||
| Q3 25 | 1.2% | — | ||
| Q2 25 | 0.2% | — | ||
| Q1 25 | 0.2% | — | ||
| Q4 24 | 1.6% | 0.1% | ||
| Q3 24 | 0.3% | 2.0% | ||
| Q2 24 | 0.5% | 18.1% | ||
| Q1 24 | 0.7% | 4.1% |
| Q4 25 | 0.22× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 4.00× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 1.06× | — | ||
| Q3 24 | 11.85× | — | ||
| Q2 24 | 38.21× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
